News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Galleon Pharmaceuticals, Inc. Announces Publication Of Proof-Of-Concept Clinical Studies For GAL-021, Projected Use For The Emerging Perioperative Sleep Apnea Epidemic


9/2/2014 11:27:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HORSHAM, Pa.--(BUSINESS WIRE)--Galleon Pharmaceuticals announced clinically and statistically significant (p<0.01) results from a double-blind, placebo-controlled clinical proof-of-concept study of its lead investigational compound GAL-021 in normal volunteers. The data were published in the most recent issue of Anesthesiology.

The study sought to assess whether GAL-021 stimulated breathing in humans with respiratory depression induced by a potent opioid under conditions common after surgery. Researchers concluded that GAL-021 met or exceeded the study’s pre-defined goals of maintaining both respiration and pain control under these conditions, and called for further clinical exploration of the drug’s safety and efficacy.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES